Phase II results for Alexion's 5G1.1

ALXN said that in a preliminary analysis of a double-blind U.S. Phase II trial of 5G1.1 in 209 patients with mild to moderate rheumatoid arthritis receiving methotrexate, the group of 53 patients rece...